WOOJUNG BIO, Inc. (KOSDAQ: 215380)
South Korea
· Delayed Price · Currency is KRW 1,869.00
-45.00 (-2.35%)
Nov 15, 2024, 9:00 AM KST
WOOJUNG BIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 44,753 | 38,616 | 46,918 | 31,238 | 37,344 | 32,290 | Upgrade
|
| Other Revenue | -0 | -0 | - | - | - | 0 | Upgrade
|
| Revenue | 44,753 | 38,616 | 46,918 | 31,238 | 37,344 | 32,290 | Upgrade
|
| Revenue Growth (YoY) | 22.76% | -17.70% | 50.20% | -16.35% | 15.65% | 35.91% | Upgrade
|
| Cost of Revenue | 35,264 | 32,427 | 40,291 | 25,490 | 32,107 | 22,555 | Upgrade
|
| Gross Profit | 9,489 | 6,189 | 6,626 | 5,748 | 5,237 | 9,736 | Upgrade
|
| Selling, General & Admin | 8,873 | 8,287 | 6,881 | 7,686 | 6,817 | 6,495 | Upgrade
|
| Research & Development | 339.95 | 294.44 | 614.06 | 538.26 | 620.94 | 1,136 | Upgrade
|
| Other Operating Expenses | 223.38 | 218.17 | 202.1 | 196.91 | 38.55 | 38.6 | Upgrade
|
| Operating Expenses | 10,295 | 10,213 | 9,148 | 9,609 | 10,642 | 9,093 | Upgrade
|
| Operating Income | -806.14 | -4,025 | -2,521 | -3,861 | -5,404 | 642.32 | Upgrade
|
| Interest Expense | -3,352 | -3,225 | -2,797 | -648.62 | -54.02 | -68.39 | Upgrade
|
| Interest & Investment Income | 40.61 | 55.26 | 78 | 51.23 | 103.55 | 223.55 | Upgrade
|
| Currency Exchange Gain (Loss) | -78.79 | -37.65 | -45.53 | 68.61 | -27.7 | 113.23 | Upgrade
|
| Other Non Operating Income (Expenses) | 5,362 | 3,953 | 4,358 | 1,336 | -3,452 | -1,203 | Upgrade
|
| EBT Excluding Unusual Items | 1,165 | -3,280 | -927.89 | -3,054 | -8,835 | -292.26 | Upgrade
|
| Gain (Loss) on Sale of Investments | -43.12 | 5.51 | -28.94 | 1,182 | -1,714 | 15.64 | Upgrade
|
| Gain (Loss) on Sale of Assets | 83.37 | 27.2 | -61.77 | -53.59 | -16.01 | 291 | Upgrade
|
| Asset Writedown | - | - | -846.94 | - | -3.06 | - | Upgrade
|
| Other Unusual Items | -24.77 | -1,807 | - | - | - | - | Upgrade
|
| Pretax Income | 1,181 | -5,054 | -1,866 | -1,926 | -10,568 | 14.38 | Upgrade
|
| Income Tax Expense | - | - | 14.66 | - | 310.22 | -265.21 | Upgrade
|
| Net Income | 1,181 | -5,054 | -1,880 | -1,926 | -10,879 | 279.59 | Upgrade
|
| Net Income to Common | 1,181 | -5,054 | -1,880 | -1,926 | -10,879 | 279.59 | Upgrade
|
| Shares Outstanding (Basic) | 13 | 13 | 13 | 12 | 12 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 16 | 13 | 12 | 12 | 10 | Upgrade
|
| Shares Change (YoY) | 41.73% | 22.07% | 7.66% | 3.36% | 15.90% | 5.75% | Upgrade
|
| EPS (Basic) | 89.49 | -394.87 | -146.00 | -161.00 | -940.00 | 28.00 | Upgrade
|
| EPS (Diluted) | -127.02 | -451.00 | -146.00 | -161.00 | -940.00 | 28.00 | Upgrade
|
| Free Cash Flow | 1,006 | -4,065 | -8,919 | -34,956 | -24,340 | -1,953 | Upgrade
|
| Free Cash Flow Per Share | 55.30 | -258.57 | -692.60 | -2922.44 | -2103.16 | -195.56 | Upgrade
|
| Gross Margin | 21.20% | 16.03% | 14.12% | 18.40% | 14.02% | 30.15% | Upgrade
|
| Operating Margin | -1.80% | -10.42% | -5.37% | -12.36% | -14.47% | 1.99% | Upgrade
|
| Profit Margin | 2.64% | -13.09% | -4.01% | -6.16% | -29.13% | 0.87% | Upgrade
|
| Free Cash Flow Margin | 2.25% | -10.53% | -19.01% | -111.90% | -65.18% | -6.05% | Upgrade
|
| EBITDA | 3,617 | 298.17 | 1,726 | -1,160 | -3,819 | 2,017 | Upgrade
|
| EBITDA Margin | 8.08% | 0.77% | 3.68% | -3.71% | -10.23% | 6.25% | Upgrade
|
| D&A For EBITDA | 4,423 | 4,323 | 4,247 | 2,701 | 1,586 | 1,375 | Upgrade
|
| EBIT | -806.14 | -4,025 | -2,521 | -3,861 | -5,404 | 642.32 | Upgrade
|
| EBIT Margin | -1.80% | -10.42% | -5.37% | -12.36% | -14.47% | 1.99% | Upgrade
|
| Advertising Expenses | - | 50.59 | 95.36 | 48.75 | 112.24 | 210.42 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.